Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Why Did Suboxone ANDA Applicant Forfeit 180-Day Exclusivity? US FDA's Answer Sets New Policy

Jul 25 2018

• By Brenda Sandburg

FDABldg1ExteriorWithCircle_1200x675

Related Content

Indivior To Appeal US Suboxone Setback, Flags Follow-On Drug RBP-6000

Sep 02 2017

Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade

Jul 11 2018

Dr. Reddy's Launches First Generic Suboxone Film; Indivior May Seek Injunction

Jun 17 2018

Related Companies

Indivior plc

Dr. Reddy's Laboratories Ltd.

Viatris Inc.

Additional Topics

United States Regulation FDA Generic Drugs Legal Issues BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window